Mayo Test ID PLFA Cryptococcus Antigen Screen, Lateral Flow Assay, Pleural Fluid
Additional Testing Requirements
Pleural fluid testing for cryptococcal antigen should also be submitted for routine fungal culture. Order FGEN / Fungal Culture, Routine.
Specimen Required
Container/Tube: Sterile vial
Specimen Volume: 0.5 mL
Useful For
Diagnosis of infection with Cryptococcus species
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
PLFAT | Cryptococcus Ag Titer, LFA, PF | No | No |
Testing Algorithm
If this screen is positive, the antigen titer will be performed at an additional charge.
Method Name
Lateral Flow Assay (LFA)
Reporting Name
Cryptococcus Ag Screen, LFA, PFSpecimen Type
Pleural FluidSpecimen Minimum Volume
0.25
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Pleural Fluid | Refrigerated (preferred) | 21 days | |
Frozen | 30 days |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Cryptococcosis is an invasive fungal infection caused by Cryptococcus neoformans or Cryptococcus gattii. C neoformans has been isolated from several sites in nature, particularly weathered pigeon droppings. C gattii was previously associated with tropical and subtropical regions only; however, more recently this organism has also been found to be endemic in British Columbia, along the Pacific Northwest, and in the Southeastern United States.
Infection is usually acquired via the pulmonary route. Patients are often unaware of any exposure history. Approximately half of the patients with symptomatic disease have a predisposing immunosuppressive condition such as AIDS, steroid therapy, lymphoma, or sarcoidosis. Symptoms may include fever, headache, dizziness, ataxia, somnolence, and cough. While the majority of C neoformans infections occur in immunocompromised patient populations, C gattii has a higher predilection for infection of healthy individuals.
In addition to the lungs, cryptococcal infections frequently involve the central nervous system (CNS), particularly in patients infected with HIV. Mortality among patients with CNS cryptococcosis may approach 25% despite antibiotic therapy. Untreated CNS cryptococcosis is invariably fatal. Disseminated disease may affect any organ system and usually occurs in immunosuppressed individuals.
Reference Values
Negative
Interpretation
The presence of cryptococcal antigen in pleural fluid is indicative of infection with Cryptococcus species.
Monitoring cryptococcal antigen levels as a means to determine response to therapy is discouraged, as antigen levels may persist despite adequate treatment and disease resolution.
A negative result indicates lack of infection; however, rare cases of false-negative results have been reported. Fungal culture should always be ordered alongside antigen testing.
Cautions
A negative result does not preclude diagnosis of cryptococcal infection, particularly if the patient is at risk for cryptococcosis and shows symptoms consistent with this disease.
False-positive results may occur in patients with trichosporonosis or infection with Capnocytophaga species.
Clinical Reference
1. Binnicker MJ, Jespersen DJ, Bestrom JE, Rollins LO: Comparison of four assays for the detection of cryptococcal antigen. Clin Vaccine Immunol. 2012 Dec;19(12):1988-1990
2. Howell SA, Hazen KC, Brandt ME: Candida, cryptococcus, and other yeast of medical importance. In: Manual of Clinical Microbiology. 11th ed. ASM Press; 2015:1984-2014
Method Description
The Cryptococcus antigen (CrAg) lateral flow assay is a sandwich immunochromatographic assay. Specimens and diluent are added to a test tube and the lateral flow device is added. The test uses specimen wicking to capture gold-conjugated, anti-cryptococcal antigen monoclonal antibodies and gold-conjugated control antibodies deposited on the test membrane. If cryptococcal antigen is present in the specimen, it binds to the gold-conjugated anti-cryptococcal antigen antibodies. This complex wicks up the membrane and interacts with the test line, which has immobilized anti-cryptococcal antigen monoclonal antibodies. The antigen-antibody complex forms a sandwich at the test line causing a visible line to form. A valid test shows a visible line at the control line. Positive test results create 2 lines (control and specimen), while negative results form only the control line.(Package insert: CrAg Lateral Flow Assay. IMMY; Rev 06/27/2019)
Day(s) Performed
Monday through Sunday
Report Available
Same day/1 to 2 daysSpecimen Retention Time
7 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
87899-Cryptococcus Ag Screen, LFA, PF
87899-Cryptococcus Ag Titer, LFA, PF (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
PLFA | Cryptococcus Ag Screen, LFA, PF | 29533-7 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
42396 | Cryptococcus Ag Screen, LFA, PF | 29533-7 |